Trial of IW-1973, A Stimulator of Soluble Guanylate Cyclase (sGC) in Patients With Stable Type 2 Diabetes and Hypertension
Status:
Completed
Trial end date:
2017-08-03
Target enrollment:
Participant gender:
Summary
To compare the safety, tolerability, pharmacokinetic (PK) profile, and pharmacodynamic (PD)
effects of 2 treatment regimens of IW-1973 tablet (40 mg per day) administered orally for 2
weeks to patients with stable type 2 diabetes mellitus and hypertension.
Phase:
Phase 2
Details
Lead Sponsor:
Cyclerion Therapeutics Ironwood Pharmaceuticals, Inc.